BioCryst’s Orladeyo Built The Cash Pile, CEO Gayer Wants To Buy The Next Asset
CEO Gayer told CNBC in an interview that the company is now profitable and plans to use that cash to invest in other rare-disease medicines. Gayer, who took the top job in January, said Orladeyo, BioCryst’s once-daily pill for hereditary angioedema, is generating the money to fund a new drug buy. BioCryst expects full-year Orladeyo … Read more